Nevertheless, identifying patients with the presence of NAFLD or elevated ALT did not affect the sensitivity of the approach and, if anything, allowed to reduce the number of biopsies by ~1 per 100 patients screened. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.